Systemic sclerosis caused by paclitaxel liposomes
10.3760/cma.j.cn114015-20240102-00001
- VernacularTitle:紫杉醇脂质体致系统性硬化病
- Author:
Jiaoyuan HUANG
1
;
Zixiang QIN
;
Liang LI
;
Tao ZHANG
Author Information
1. 广州中医药大学中医内科专业，广州 510006
- Publication Type:Journal Article
- Keywords:
Scleroderma, systemic;
Paclitaxel liposomes;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2024;26(12):759-762
- CountryChina
- Language:Chinese
-
Abstract:
A 55-year-old female patient with ovarian cancer received bevacizumab (intravenous infusion of 400 mg on day 1) and paclitaxel liposomes (intravenous infusion of 180 mg on day 1) 9 years after surgery due to disease progression, with 21 days as a cycle of chemotherapy. Due to the improvement of the patient′s general condition, the chemotherapy regimens for the 3rd and 4th cycles were adjusted to addtionally give intravenous infusion of carboplatin 500 mg on day 1, and in the 5th cycle, the dose of bevacizumab was increased to 700 mg. Starting from the 2th cycle of chemotherapy, after each intravenous infusion of paclitaxel, the patient immediately experienced itching symptoms on the distal skin of both upper limbs, which were mild and could be relieved on their own. After the 5th cycle of chemotherapy, the patient′s itching symptoms worsened progressively. Four days later, keratinization of the skin on both hands and forearms of upper limbs appeared, with tight skin and waxy luster, gradually developing towards the proximal end. The modified Rodnan skin score was 1-2 (mild to moderate skin thickening). Laboratory tests showed positive results for anti-nuclear antibodies and anti-centromere antibodies.Pathological examination of skin biopsy tissue of the right forearm showed dermal fibrosis, involving subcutaneous adipose tissue and epidermal atrophy. It was considered to be localized cutaneous systemic sclerosis caused by paclitaxel liposomes. Paclitaxel liposomes was stopped and anti-inflammatory and topical application of glucocorticoids locally treatments were given for 3 days, the patient′s itching symptoms were improved. At a 2-month follow-up, the patient′s itching symptoms were improved and did not recur.
